Treatment of mild to moderate Ulcerative Colitis

Adult: For adults, the recommended dosage of Mesagut is 800 mg (two 400 mg tablets) three times daily for a duration of 6 weeks. However, a dose up to 4.8 g/day in divided doses may be given if needed.

Child: For child patients 5 years of age and older, daily dosage of Mesagut is as follows:


















 

Maintenance of remission of mild to moderate Ulcerative Colitis
Adult: The recommended dosage of Mesagut is 1.6 g (four 400 mg tablets) daily in two to four divided doses. However, a dose up to 2.4 g/day in divided doses may be given if needed.

Maintenance of remission of Crohn's disease
Adult: 1.2-2.4 g daily in divided dose.
Child: 400-800 mg 3 times daily.

Mesalazine is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Mesalazine.

Renal Impairment: Evaluate renal function in all patients prior to initiation and periodically while on mesalazine therapy.
Hepatic Impairment: Evaluate the risks and benefits of using mesalazine in patients with known liver impairment.

The common side effects are nausea, vomiting, dizziness, asthenia, dyspepsia, rash, fatigue, pruritis etc.

The concurrent use of mesalazine with known nephrotoxic agents, including NSAIDs may increase the risk of nephrotoxicity & use of mesalazine with azathioprine or 6-mercaptopurine may increase the risk of blood disorder

Pregnant Women: It should be given in pregnancy only if the potential benefit justifies the potential risk to the foetus.
Lactating mother: Caution is advised when it is administered to a nursing women.
Geriatrics: Patients who are 65 years or older, caution should be taken to closely monitor blood cell counts during mesalazine therapy.

Mesagut Tablet: Each box contains 30 tablets in alu-alu blister pack.